DRUG · Mapped RxNorm record
Durvalumab
Normalized identity: durvalumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Real-world Study of Durvalumab for Lung Cancer in China
NCT04672759
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Durvalumab
Normalized identity: durvalumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Real-world Study of Durvalumab for Lung Cancer in China
Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non Small Cell Lung Cancer Stage IIIunresolved
Small-Cell Lung Cancerunresolved
Interventions
DurvalumabDRUG · verified · RxNorm: durvalumab
DurvalumabDRUG · verified · RxNorm: durvalumab
Sponsors & collaborators
Peking Union Medical College Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04672759 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.